The effect of nirmatrelvir‐ritonavir on viral clearance and length of hospital stay in patients infected with SARS‐CoV‐2 omicron variants

BACKGROUND: The pandemic of coronavirus disease 2019 (COVID‐19) has caused heavy burdens on national healthcare systems. Nirmatrelvir‐ritonavir (Paxlovid) may be one of the most promising therapeutic drugs, with reports of up to 89% reduction rates in hospitalization risk and death among patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yu, Zhao, Danyang, Chen, Xubo, Liu, Xinbing, Xiao, Wenying, Feng, Liuliu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Short Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9946694/
https://www.ncbi.nlm.nih.gov/pubmed/36843224
http://dx.doi.org/10.1111/irv.13095

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9946694/
https://www.ncbi.nlm.nih.gov/pubmed/36843224
http://dx.doi.org/10.1111/irv.13095

Ejemplares similares